Paula Franco

Dr. Paula Franco


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2022 in Acta Medica Philippina
Verified
Journal Article
Open access
PDF file
PFPaula Franco
Paula Franco
LPLia M. Palileo-Villanueva
Lia M. Palileo-Villanueva
PCPatricia Maria Gregoria M. Cuaño
Patricia Maria Gregoria M. Cuaño
MBMa. Rosario E. Bayan
Ma. Rosario E. Bayan
BRBayan Ma. Rosario
Bayan Ma. Rosario
JMJhaki A. Mendoza
Jhaki A. Mendoza
Objectives. Internal Medicine physician trainees faced unique challenges as the primary frontline physicians at a tertiary COVID-19 government referral center during the COVID-19 pandemic. This study examined the prevalence of burnout and resilience of these physician trainees during the early period of the pandemic, the determinants of burnout, and their sources of anxiety and coping mechanisms. Methods. Using a mixed-methods approach, we conducted an online cross-sectional survey to measure burnout and resilience among 196 Internal Medicine physician trainees using the Maslach Burnout Index Human Services Survey for Medical Personnel and the Connor-Davidson Resiliency questionnaires, respectively. We then conducted virtual focus group discussions and in-depth key informant interviews to explore the trainees’ sources of anxiety and coping mechanisms until thematic saturation was satisfied. Results. Out of 146 respondents (from 196 eligible participants, 74% response rate), four percent of physician trainees fit the frank burnout profile, 40% were engaged, while the majority had intermediate profiles (23% ineffective, 28% overextended, and 4% disengaged). The mean resilience score was 72.9 (SD 12.4). Resilience was a significant negative predictor for burnout (Beta Coefficient = -0.73, p<0.001). Its protective effect decreases in those with more exposure to patient deaths (Beta Coefficient = 6.767, p<0.05). Significant sources of anxiety included changes in the practice of medicine (changes in workflow, working in full personal protective equipment, telemedicine and zoom fatigue, constant threat of acquiring the infection) and having competing demands between service and training. Coping mechanisms included preserving a haven, maintaining social relationships, and self-care. Conclusion. In the largest government hospital in the Philippines, four percent of Internal Medicine physician trainees had burnout, 40% were engaged, and the majority were at-risk for burnout a few months into the COVID-19 pandemic in 2020. Resilience reduces the risk for burnout. However, its protective effect decreased with exposure to a higher number of patient deaths per week.

27 March 2026 in ESMO Real World Data and Digital Oncology
Verified
Journal Article
Open access
PMPablo Mandó
Pablo Mandó
Myrto MoutafiMyrto Moutafi
Myrto Moutafi
ECE.A. Connolly
E.A. Connolly
LFL. Faulkner
L. Faulkner
PFPaula Franco
Paula Franco
Matteo LambertiniMatteo Lambertini
Matteo Lambertini
Digital health technologies are transforming oncology care, yet adoption remains inconsistent globally. This study evaluates current utilization patterns, perceived effectiveness, and barriers among oncology professionals worldwide. We conducted a global cross-sectional survey (27 questions) analyzing workplace characteristics, technology usage patterns, effectiveness, and barriers to adoption among oncology professionals to better understand the real-world adoption of digital health technologies. Using a questionnaire developed by the ESMO Young Oncologists Committee in collaboration with the medical student alumni, we assessed device availability, technology usage, effectiveness ratings, training experiences, and implementation barriers. Responses were analyzed using descriptive statistical methods to identify usage patterns, variations and barriers to adoption of digital health technologies. A total of 423 oncology professionals completed the questionnaire. The survey revealed widespread access to computerized workstations (89.1%) but notable geographic disparities (Africa 67.7% versus Europe 93.8%, P < 0.001). Email remained the most widely used communication tool (51.8%), while video telehealth was rated as the most effective (62.9% scoring 4-5 on a 5-point Likert scale). Despite 46.8% of oncology professionals reporting using telemedicine systems, only 28.2% received formal training. Respondents reported an increase of adoption of digital health solutions in 93.3% of the cases. Older clinicians (>40 years) showed 12% higher video telehealth usage than younger colleagues (35% versus 23%, P = 0.014). Major barriers included system integration challenges (67.4%) and infrastructure limitations (57.3%), while 84.1% expressed a need for additional training. Effectiveness varied significantly by tool, from 80.5% for e-prescriptions to 45.2% for telemonitoring. Regional patterns emerged, with high-bandwidth tools predominant in well-resourced areas (Oceania 85.7% video telehealth) versus text-based systems where connectivity is more limited (Africa 63% chat-based). Findings from the present survey highlight persistent disparities in digital health adoption, emphasizing the need for infrastructure investment, interoperable systems, and tailored training to ensure equitable implementation and maximize the potential of technology in oncology care globally.

15 June 2023 in ecancermedicalscience
Verified
Journal Article
Open access
PFPaula Franco
Paula Franco
APAnna Pascual-Panganiban
Anna Pascual-Panganiban
The parotid gland, an unusual site of colorectal cancer metastasis Paula Isabel G Francoa and Anna Pascual-Panganiban Section of Medical Oncology, St Lu

1 June 2024 in JCO Global Oncology
Verified
Journal Article
Closed access
PFPaula Franco
Paula Franco
JAJose Jasper Andal
Jose Jasper Andal
DADaphne Chua Ang
Daphne Chua Ang
FQFrances Victoria Que
Frances Victoria Que
PURPOSE: In high-income countries, 2%-10% of tumor genomic profiling (TGP) reports reveal incidental pathogenic germline variants. A third of these patients would not qualify for genetic testing on the basis of current guidelines. Our study determined the prevalence of potentially pathogenic germline variants (PPGVs) in TGP results of adult patients with solid malignancies in the Philippines. METHODS: Annotated reports of patients with solid cancers who underwent TGP using FoundationOne or FoundationOne Heme between January 2021 and July 2023 were reviewed. PPGV criteria include having a variant allele frequency of >30% and were categorized as (1) high penetrance gene (HP), founder variant (FV), or variant associated with clinical presentation (VA). Pathogenicity was crosschecked through the ClinVar database. RESULTS: Of 446 patients, 13 PPGV variants were found in 50 (11.2%) patients at a median age of 60.5 years. Of them, 28 (56%) had HP ( BRCA1, BRCA2, MSH2, MSH6, MLH1, RAD51C, RAD51D), 25 (50%) patients had VA ( APC, SMAD4, CDH1, CDKN2A, PTEN), and two patients with lung cancer had a FV ( EGFR p.Thr790Met). Six patients had more than one PPGV. PPGVs were primarily found in patients with colorectal (42% of 50 patients with PPGVs), breast (16%), ovarian (6%), and lung (6%) cancer ( P < .001). HP genes were mostly found in female patients (71.4%; P = .03). CONCLUSION: With a PPGV prevalence of 11% in this study, it is important to recognize PPGVs as it can prompt genetic counseling and confirmatory germline testing.

25 August 2026 in ESMO Open
Verified
Journal Article
Open access
AWA.N.M. Wong
A.N.M. Wong
PFPaula Franco
Paula Franco
HSH.S. Sheikh
H.S. Sheikh
OPO. Pitiyarachchi
O. Pitiyarachchi
NPN. Prasongsook
N. Prasongsook
NCN. Cherny
N. Cherny
The European Society for Medical Oncology (ESMO) conducted a global survey on the availability, out-of-pocket costs (OPCs), and accessibility of cancer medicines in 2015, with an updated survey in 2023. The Asia-Pacific (APAC) region accounts for approximately half of global cancer-related deaths, yet substantial disparities persist in access to essential cancer medicines. A focused analysis of the 2023 ESMO global survey was undertaken to evaluate access trends specific to the APAC region. Data from the 2023 ESMO global survey were analysed to assess the availability, access, and OPC of cancer medicines in APAC countries, using the World Health Organization's Essential Medicines List as a benchmark. Countries included in the analysis were Australia, Taiwan (China), Japan, New Zealand, Republic of Korea, Singapore, China, Malaysia, Thailand, Bangladesh, Cambodia, India, Indonesia, Mongolia, Myanmar, Nepal, Papua New Guinea, Philippines, Vanuatu, and Vietnam. Selected case studies, including immunotherapy and oral targeted therapies, were used to explore access and regulatory approval timelines. A descriptive comparison of health technology assessment processes across APAC countries was also conducted. Availability and access to antineoplastic medicines in APAC remain limited, particularly in low- and middle-income countries. Although novel therapies are generally available, they often incur substantial OPC burdens on patients. The case studies reveal considerable delays in regulatory approval for both immunotherapy and targeted therapies across the region. Despite the introduction of innovative cancer therapies, substantial inequities in access and availability persist across APAC. Coordinated regional policies and streamlined regulatory processes may improve equitable access in the region.